Antares Pharma

Antares Pharma FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Antares Pharma (ATRS) as of Nov 2, 2026 is 64.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 11.93 % — a change of 443.27% (higher).

FCF Conversion

64.81 %

YoY

443.27%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Antares Pharma is 2021 64.81 % . FCF Conversion Rate (FCF/EBITDA) of Antares Pharma was 2020 11.93 % . It decreases by 443.27% higher compared to the previous year.

The Antares Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
91.00 USD
Jan 1, 2015
168.86 USD
Jan 1, 2016
83.00 USD
Jan 1, 2017
145.51 USD
Jan 1, 2018
279.60 USD
Jan 1, 2019
639.62 USD
Jan 1, 2020
11.93 USD
Jan 1, 2021
64.81 USD
The Antares Pharma FCF Conversion history
YEARFCF ConversionYoY
64.81 %+443.27%
11.93 %-98.13%
639.62 %+128.76%
279.60 %+92.16%
145.51 %+75.30%
83.00 %-50.85%
168.86 %+85.58%
91.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Antares Pharma Stock analysis

What does Antares Pharma do? The company Antares Pharma Inc was founded in 1979 in Minneapolis, USA. It has since become a successful company in the field of drug development and marketing. The company has been listed on the NASDAQ since 2006. Antares Pharma is a pharmaceutical company specializing in the development of injectable medications. Their business model is to develop innovative injectable products that meet the needs of patients and doctors, and are able to improve their therapy experience and increase adherence. The company specializes in three areas: self-injection systems, automatic devices, and pharmaceutical products. The innovation power behind Antares Pharma's development work is an important factor in their success, as well as their skills in market research and marketing. One of the company's main products is the VIBEX Pen, an automatic injection device that can be operated by patients themselves and filled with various therapeutics. The device provides an easy and painless way to administer medications. The company also produces the Makena auto-injector, which is used in pregnancy treatment. Another important product is the QuickShot auto-injector, a proprietary device used by patients to administer hormone preparations, immunomodulators, and various other common therapeutics. Due to its many years of experience and good reputation in the market, Antares Pharma has strong collaborative relationships with the pharmaceutical industry. The company's customers include reputable pharmaceutical companies such as Pfizer, Teva, Merck, and Novartis, who utilize the company's expertise to bring their own products to the market. Antares Pharma is headquartered in Ewing Township, New Jersey, USA. The company employs a variety of research and development experts who are constantly working to develop new medications and therapy approaches. It has strengthened its position as a major player in the pharmaceutical market and its goal remains to continue creating innovative solutions in the industry. Answer: Antares Pharma Inc. is a successful pharmaceutical company specializing in the development and marketing of injectable medications. They are known for their innovative products that improve therapy experiences and increase adherence. With a strong presence in the pharmaceutical market, Antares Pharma collaborates with renowned companies and continues to strive for innovative solutions. Antares Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Antares Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Antares Pharma is 64.81 % in 2021.

FCF Conversion Rate (FCF/EBITDA) of Antares Pharma changed from 11.93 % to 64.81 %, representing a 443.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Antares Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Antares Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Antares Pharma

All Key Metrics — Antares Pharma